MedTrace Logo

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

NCT02221960 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2019-03-13

No results posted yet for this study

Summary

To evaluate MEDI6383 when given alone or together with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.

Conditions

  • Recurrent or Metastatic Solid Tumors

Interventions

BIOLOGICAL

MEDI6383

Subjects will receive MEDI6383 until disease progression or adverse event.

BIOLOGICAL

MEDI6383 and MEDI4736

Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Medimmune Medimmune · MedImmune LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-15
Primary Completion
2017-07-03
Completion
2017-07-03

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02221960 on ClinicalTrials.gov